Adamas Pharmaceuticals Company Profile (NASDAQ:ADMS)

Analyst Ratings

Consensus Ratings for Adamas Pharmaceuticals (NASDAQ:ADMS) (?)
Ratings Breakdown: 9 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $32.00 (111.92% upside)

Analysts' Ratings History for Adamas Pharmaceuticals (NASDAQ:ADMS)
Show:
DateFirmActionRatingPrice TargetActions
7/25/2016Credit Suisse Group AGReiterated RatingBuy$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/22/2016Noble FinancialReiterated RatingBuy$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/20/2016Needham & Company LLCReiterated RatingBuy$38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/23/2016MizuhoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/15/2016JMP SecuritiesReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/14/2016Piper Jaffray Cos.Reiterated RatingOverweight$44.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/26/2016AegisReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/11/2015William BlairReiterated RatingOutperform$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Adamas Pharmaceuticals (NASDAQ:ADMS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/9/2016        
5/10/2016Q1($0.76)($0.65)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/23/2016Q4($0.81)($0.58)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2015Q215($0.72)($0.78)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2015Q414($0.74)($0.69)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2015$0.64$0.50ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2014Q314($0.44)($0.57)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214$0.81$0.88$18.75 million$25.15 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014Q114($0.09)($0.67)$30.60 million$0.18 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Adamas Pharmaceuticals (NASDAQ:ADMS)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.61)($0.61)($0.61)
Q2 20161($0.71)($0.71)($0.71)
Q3 20161($0.88)($0.88)($0.88)
Q4 20161($0.90)($0.90)($0.90)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Adamas Pharmaceuticals (NASDAQ:ADMS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Adamas Pharmaceuticals (NASDAQ:ADMS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
4/18/2016Natalie McclureSVPSell36,000$18.50$666,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/7/2015Ivan M LieberburgDirectorSell3,000$16.23$48,690.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/5/2015Ivan M LieberburgDirectorSell3,000$16.75$50,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015Ivan M LieberburgDirectorSell3,000$19.13$57,390.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2015Ivan M LieberburgDirectorSell3,000$25.91$77,730.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2015Natalie McclureSVPSell2,000$18.95$37,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2015Ix Lp MdvMajor ShareholderSell1,643$18.04$29,639.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2015Richard H BoothDirectorSell1,000$17.85$17,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2015Gregory T WentCEOSell2,728$18.00$49,104.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/23/2015Gregory T WentCEOSell3,300$18.00$59,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/21/2015Gregory T WentCEOSell962$18.01$17,325.62View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/20/2015Gregory T WentCEOSell2,610$18.00$46,980.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2015Richard H BoothDirectorSell1,000$17.72$17,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/14/2015Gregory T WentCEOSell14,757$7.15$105,512.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/10/2015William W EricsonDirectorSell37,078$18.56$688,167.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/6/2015Ivan M LieberburgDirectorSell3,000$17.44$52,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/6/2015Natalie McclureSVPSell2,000$17.44$34,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2015Gregory T WentCEOSell23,088$18.00$415,584.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/18/2015Ix Lp MdvMajor ShareholderSell11,723$18.02$211,248.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2015Richard H BoothDirectorSell1,000$17.36$17,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/13/2015Aeris Capital Equity InvestmenMajor ShareholderSell350,000$17.23$6,030,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2015Richard H BoothDirectorSell1,000$16.54$16,540.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/5/2015Natalie McclureSVPSell2,000$16.87$33,740.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015Ivan M LieberburgDirectorSell3,000$16.77$50,310.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2015Ivan M LieberburgDirectorSell3,000$17.59$52,770.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2015Natalie McclureSVPSell2,000$17.59$35,180.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/24/2014Richard H BoothDirectorSell2,000$17.51$35,020.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2014Aeris Capital Equity InvestmenMajor ShareholderSell111,625$14.51$1,619,678.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Aeris Capital Equity InvestmenMajor ShareholderSell13,615$14.54$197,962.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Natalie McclureSVPSell20,000$14.50$290,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/26/2014Aeris Capital Equity InvestmenMajor ShareholderSell12,500$14.77$184,625.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Aeris Capital Equity InvestmenMajor ShareholderSell10,000$14.85$148,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2014William W EricsonDirectorBuy300,000$16.00$4,800,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Adamas Pharmaceuticals (NASDAQ:ADMS)
DateHeadline
07/30/16 02:24 PMAdamas Pharmaceuticals Inc. (ADMS) Jumps 5.15% on July 29 - Equities.com
07/29/16 02:19 PMCan Shares Of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Hit $45? - Investor Newswire
07/27/16 10:58 AMAdamas Pharmaceuticals Inc. (ADMS) Drops 6.32% on July 25 - Equities.com
07/25/16 07:21 AMAdamas Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ADMS-US : July 25, 2016 -
07/23/16 02:18 PMStock Displaying Signs of a Downtrend: Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) - Press Telegraph
07/23/16 02:18 PMAdamas Pharmaceuticals Inc. (ADMS) is Trading Higher on Unusual Volume for July 21 - Equities.com
07/22/16 02:17 PMIs $45 Price Target Attainable For Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)? - Investor Newswire
07/21/16 07:53 PMAdamas Pharmaceuticals Inc. (ADMS) Jumps 9.66% on July 21 - Equities.com
07/21/16 02:18 PMStock Soars, Rewards Investors Nicely Today: Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) - Engelwood Daily
07/21/16 02:18 PMStock Marching Up in Session: Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) - TGP
07/21/16 02:18 PMBiotech Movers: Adamas Pharmaceuticals Inc (NASDAQ:ADMS), Relypsa Inc (NASDAQ:RLYP) and Biogen Inc ... - Market Exclusive
07/21/16 02:18 PMAdamas Pharmaceuticals Inc (NASDAQ:ADMS)'s Company Shares Decreased 10.89% After Low Volatility - Consumer Eagle
07/21/16 10:47 AMBroker Outlook For Adamas Pharmaceuticals, Inc. (ADMS) - Fiscal Standard
07/19/16 01:26 PMAdamas Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ADMS) : July 19, 2016 -
07/19/16 08:30 AMAdamas Pharmaceuticals Incorporated (NASDAQ:ADMS) Short Interest Increased By 12.91% - Press Telegraph
07/19/16 08:30 AMAllergan (AGN), Adamas Pharma (ADMS) Announce Expanded NAMZARIC Indication - StreetInsider.com
07/17/16 07:04 AMShares Moving Down on the Week: Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) - Engelwood Daily
07/17/16 07:04 AMNext Weeks Broker Price Targets For Adamas Pharmaceuticals, Inc. (ADMS) - Fiscal Standard
07/16/16 02:18 PMGreat Point Partners LLC Increased Adamas Pharmaceuticals INC (NASDAQ:ADMS) by $9.40 Million as Shares ... - Consumer Eagle
07/16/16 02:18 PMStrong Sell Calls For Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) At 0 - Investor Newswire
07/16/16 02:18 PMAdamas Pharmaceuticals Incorporated (NASDAQ:ADMS) Short Interest Decreased By 4.19% - Consumer Eagle
07/14/16 02:19 PMEye on Stock Volatility for: Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) - Engelwood Daily
07/13/16 07:04 AMAdamas Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ADMS-US : July 13, 2016 -
07/12/16 07:47 PMAdamas Pharmaceuticals Inc. (ADMS) Jumps 6.2% on July 12 - Equities.com
07/08/16 07:30 PMIs $45 Within Reach For Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)? - Investor Newswire
07/07/16 02:19 PMWhy Adamas Pharmaceuticals (ADMS) Stock Might be a Great Pick - Nasdaq
07/07/16 07:39 AMWhy Adamas Pharmaceuticals (ADMS) Stock Might be a Great Pick -
07/04/16 07:05 AMAdamas Pharmaceuticals Incorporated (NASDAQ:ADMS) Shorts Decreased by 4.19% After Short Covering - Press Telegraph
07/01/16 04:46 PMETF’s with exposure to Adamas Pharmaceuticals, Inc. : July 1, 2016 -
07/01/16 02:19 PMAdamas Pharmaceuticals, Inc. (ADMS) Updated Price Targets - FTSE News
07/01/16 10:16 AMGreat Point Partners LLC Increased Adamas Pharmaceuticals INC (NASDAQ:ADMS) by $9.40 Million as Shares ... - Press Telegraph
06/30/16 02:19 PMUpdate on Stock Volatility for: Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) - Engelwood Daily
06/29/16 03:31 PMAdamas Pharmaceuticals to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference - [at noodls] - EMERYVILLE, Calif., June 29, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, will present ...
06/29/16 02:16 PMBrokers Issue Average Price Target Of 33.78 On Adamas Pharmaceuticals, Inc. (ADMS) - Fiscal Standard
06/29/16 02:16 PMAdamas Pharmaceuticals Inc. (ADMS) Jumps 5.43% on June 28 - Equities.com
06/29/16 12:28 PM16 Biopharma Companies Besides Medivation That Are Attractive Targets -
06/25/16 02:19 PMStock Grabbing Investor's Attention: Adamas Pharmaceuticals, Inc. (ADMS) - iStreetWire
06/24/16 02:19 PMStrong Sell Calls Recommendations For Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) At 0 - Investor Newswire
06/24/16 10:27 AMTaking A Look At Adamas Pharmaceuticals Inc (ADMS)'s Upcoming Parkinson's NDA - Insider Monkey (blog)
06/23/16 12:10 PMTaking A Look At Adamas Pharmaceuticals Inc (ADMS)’s Upcoming Parkinson’s NDA -
06/23/16 10:03 AMAdamas Pharma (ADMS) Offers Additional Data from ADS-5102 Phase 3 in LID; Improvement in All Subgroups Noted
06/22/16 07:30 PMAdamas Pharmaceuticals Inc. (ADMS) Drops 7.97% on June 21 - Equities.com
06/22/16 02:19 PMAdamas Pharmaceuticals (ADMS) Weak On High Volume Today - TheStreet.com
06/22/16 07:05 AMAdamas Pharma (ADMS) Offers Additional Data from ADS-5102 Phase 3 in LID; Improvement in All Subgroups Noted - StreetInsider.com
06/22/16 05:09 AMAdamas Announces Additional ADS-5102 Data for the Treatment of Levodopa-induced Dyskinesia at the International Congress of Parkinson's Disease and Movement Disorders - [at noodls] - EMERYVILLE, Calif., June 22, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced additional data from its Phase 3 clinical program of ADS-5102 (amantadine HCl) extended-release ...
06/22/16 05:01 AM6:01 am Adamas Pharmaceuticals announces additional data from its Phase 3 clinical program of ADS-5102 extended-release capsules for the treatment of levodopa-induced dyskinesia associated with Parkinson's disease at the International Congr -
06/22/16 05:00 AMAdamas Announces Additional ADS-5102 Data for the Treatment of Levodopa-induced Dyskinesia at the International Congress of Parkinson’s Disease and Movement Disorders - [GlobeNewswire] - EMERYVILLE, Calif., June 22, 2016-- Adamas Pharmaceuticals, Inc. today announced additional data from its Phase 3 clinical program of ADS-5102 extended-release capsules for the treatment of levodopa-induced ...
06/21/16 02:16 PMAdamas Pharmaceuticals, Inc. (ADMS) Current Analyst Ratings - Fiscal Standard
06/20/16 08:50 AMAnalyst Views For The Week Ahead: Adamas Pharmaceuticals, Inc. (ADMS) - Fiscal Standard
06/18/16 02:18 PMStrong Buy Calls Count For Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) At 6 - Investor Newswire

Social

About Adamas Pharmaceuticals

Adamas Pharmaceuticals logoAdamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. Its ADS-5102 is an extended-release version of amantadine that is intended for once daily administration at bedtime. It is developing ADS-8704, which is a fixed-dose combination of its controlled release version of memantine and donepezil for the treatment of moderate to severe dementia related to Alzheimer's disease. Its ADS 8902, a triple combination antiviral drug therapy for influenza. It also offers Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules (formerly MDX-8704) and Namenda XR (memantine hydrochloride) extended release capsules.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ADMS
  • CUSIP:
Key Metrics:
  • Previous Close: $14.36
  • 50 Day Moving Average: $15.69
  • 200 Day Moving Average: $16.11
  • P/E Ratio: N/A
  • P/E Growth: -0.06
  • Market Cap: $326.57M
  • Beta: 0.57
  • Current Year EPS Consensus Estimate: $-3.09 EPS
  • Next Year EPS Consensus Estimate: $-2.80 EPS
Additional Links:
Adamas Pharmaceuticals (NASDAQ:ADMS) Chart for Saturday, July, 30, 2016